VERA
Vera Therapeutics, Inc. NASDAQ Listed May 14, 2021$35.88
Mkt Cap $2.6B
52w Low $18.76
45.9% of range
52w High $56.05
50d MA $39.84
200d MA $35.21
P/E (TTM)
-7.5x
EV/EBITDA
-10.2x
P/B
3.7x
Debt/Equity
0.1x
ROE
-49.6%
P/FCF
-13.5x
RSI (14)
—
ATR (14)
—
Beta
1.17
50d MA
$39.84
200d MA
$35.21
Avg Volume
1.2M
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
8000 Marina Boulevard · Brisbane, CA 94005 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 36.60 | -0.4% | -2.0% | — | — | — | — | — |
| Feb 26, 2026 | BMO | -1.34 | -1.39 | -3.7% | 42.35 | -3.8% | -3.7% | +0.0% | -0.9% | -2.8% | +0.9% | — |
| Nov 5, 2025 | BMO | -1.20 | -1.26 | -5.0% | 24.10 | -2.6% | +4.6% | +0.0% | -4.1% | +14.7% | +7.1% | — |
| Aug 5, 2025 | BMO | -0.82 | -1.20 | -46.3% | 20.64 | -2.7% | -6.7% | +0.0% | +2.4% | +0.4% | +1.9% | — |
| May 6, 2025 | BMO | -0.75 | -0.81 | -8.0% | 22.01 | -1.2% | +2.8% | +0.0% | -2.6% | -1.5% | +3.6% | — |
| Feb 26, 2025 | BMO | -0.83 | -0.72 | +13.3% | 27.77 | +2.1% | +5.9% | +0.0% | +1.8% | -5.1% | +0.7% | — |
| Nov 7, 2024 | BMO | -0.69 | -0.85 | -23.2% | 49.04 | -1.5% | -1.9% | +0.0% | +1.2% | -0.3% | +1.8% | — |
| Aug 8, 2024 | BMO | -0.58 | -0.62 | -6.9% | 35.85 | -2.8% | +0.4% | +0.0% | -0.4% | +5.9% | -0.1% | — |
| May 9, 2024 | BMO | -0.53 | -0.56 | -5.7% | 42.33 | +1.9% | -2.4% | +0.0% | -1.4% | +0.3% | +4.5% | — |
| Mar 20, 2024 | BMO | -0.53 | -0.58 | -9.4% | 45.33 | +2.5% | -5.4% | +0.0% | -4.4% | +0.4% | +1.0% | — |
| Nov 9, 2023 | BMO | -0.50 | -0.45 | +10.0% | 11.51 | +12.9% | +5.5% | +0.0% | +5.1% | +6.7% | -1.9% | — |
| Aug 10, 2023 | BMO | -0.69 | -0.46 | +33.3% | 19.64 | +0.4% | -6.0% | +0.0% | -3.6% | -0.6% | -2.8% | — |
| May 11, 2023 | BMO | -0.60 | -0.80 | -33.3% | 7.55 | +0.1% | +0.3% | +0.0% | +5.3% | -3.4% | -1.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11 | Wolfe Research | Upgrade | Peer Perform → Outperform | — | $40.25 | $41.04 | +2.0% | +4.4% | -2.1% | -2.9% | +0.2% | -1.8% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.79 | $39.95 | -2.1% | -0.9% | -2.8% | +0.9% | -2.0% | +0.6% |
| Dec 19 | BofA Securities | Maintains | Buy → Buy | — | $47.69 | $48.24 | +1.2% | +7.4% | +5.0% | +0.2% | +3.3% | -3.8% |
| Dec 19 | JP Morgan | Maintains | Overweight → Overweight | — | $47.69 | $48.24 | +1.2% | +7.4% | +5.0% | +0.2% | +3.3% | -3.8% |
| Dec 19 | Goldman Sachs | Maintains | Buy → Buy | — | $47.69 | $48.24 | +1.2% | +7.4% | +5.0% | +0.2% | +3.3% | -3.8% |
| Dec 11 | Wedbush | Maintains | Neutral → Neutral | — | $44.34 | $44.27 | -0.2% | +3.8% | +8.2% | -1.2% | -1.8% | +0.5% |
| Dec 8 | Evercore ISI | Maintains | Outperform → Outperform | — | $44.90 | $44.88 | -0.0% | +0.3% | -0.8% | -0.7% | +3.8% | +8.2% |
| Dec 5 | TD Cowen | Maintains | Buy → Buy | — | $42.61 | $43.53 | +2.2% | +5.4% | +0.3% | -0.8% | -0.7% | +3.8% |
| Nov 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.19 | $26.00 | +7.5% | +14.7% | +7.1% | +4.6% | -8.7% | -0.1% |
| Nov 7 | JP Morgan | Maintains | Overweight → Overweight | — | $25.22 | $24.99 | -0.9% | -4.1% | +14.7% | +7.1% | +4.6% | -8.7% |
| Aug 7 | JP Morgan | Maintains | Overweight → Overweight | — | $19.25 | $19.21 | -0.2% | +2.4% | +0.4% | +1.9% | +4.8% | +3.9% |
| Aug 4 | Wolfe Research | Downgrade | Outperform → Peer Perform | — | $20.95 | $20.31 | -3.1% | -2.4% | +0.9% | -6.7% | +2.4% | +0.4% |
| Jun 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.95 | $31.74 | +67.5% | +67.5% | -2.6% | +3.5% | -4.3% | -25.9% |
| Jun 2 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $18.95 | $31.74 | +67.5% | +67.5% | -2.6% | +3.5% | -4.3% | -25.9% |
| May 12 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $21.71 | $22.48 | +3.5% | +3.6% | -4.0% | -1.8% | +0.7% | -0.4% |
| May 7 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $22.01 | $21.75 | -1.2% | +2.8% | -2.6% | -1.5% | +3.6% | -4.0% |
| May 7 | Wedbush | Maintains | Neutral → Neutral | — | $22.01 | $21.75 | -1.2% | +2.8% | -2.6% | -1.5% | +3.6% | -4.0% |
| Mar 4 | JP Morgan | Maintains | Overweight → Overweight | — | $28.41 | $28.06 | -1.2% | +0.7% | +4.8% | -2.2% | -1.6% | -3.5% |
| Feb 27 | Guggenheim | Maintains | Buy → Buy | — | $27.77 | $28.35 | +2.1% | +5.9% | +1.8% | -5.1% | +0.7% | +4.8% |
| Nov 8 | Wedbush | Maintains | Neutral → Neutral | — | $49.04 | $48.29 | -1.5% | -1.9% | +1.2% | -0.3% | +1.8% | -0.9% |
| Nov 5 | JP Morgan | Maintains | Overweight → Overweight | — | $45.17 | $45.24 | +0.2% | +5.6% | +0.5% | +2.3% | -1.9% | +1.2% |
| Oct 28 | Guggenheim | Maintains | Buy → Buy | — | $41.09 | $49.90 | +21.4% | +15.2% | -9.2% | -5.4% | -0.6% | +8.5% |
| Oct 3 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $41.75 | $41.66 | -0.2% | -3.0% | +0.9% | -2.0% | -3.4% | +0.8% |
| Oct 1 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $44.20 | $43.77 | -1.0% | -3.1% | -2.5% | -3.0% | +0.9% | -2.0% |
| Sep 23 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $42.78 | $42.58 | -0.5% | +4.2% | +4.8% | -3.8% | +1.6% | -4.9% |
| Sep 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $37.51 | $37.62 | +0.3% | +6.9% | -0.2% | +0.8% | +4.1% | +1.9% |
| Sep 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $37.20 | $37.38 | +0.5% | +2.9% | -1.9% | +0.1% | -5.1% | +5.2% |
| Sep 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $38.16 | $38.36 | +0.5% | -2.5% | +2.9% | -1.9% | +0.1% | -5.1% |
| Sep 3 | JP Morgan | Maintains | Overweight → Overweight | — | $37.82 | $38.56 | +2.0% | +1.4% | +0.1% | -0.6% | -2.5% | +2.9% |
| Aug 13 | JP Morgan | Maintains | Overweight → Overweight | — | $35.84 | $35.81 | -0.1% | +5.9% | -0.1% | -1.7% | +1.0% | +4.7% |
| May 31 | JP Morgan | Maintains | Overweight → Overweight | — | $36.95 | $37.62 | +1.8% | +2.8% | +6.0% | -2.0% | +4.3% | -7.7% |
| May 10 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $42.33 | $43.14 | +1.9% | -2.4% | -1.4% | +0.3% | +4.5% | -1.8% |
| Apr 5 | Guggenheim | Maintains | Buy → Buy | — | $37.41 | $37.14 | -0.7% | +0.3% | +3.0% | -1.9% | +9.8% | +17.3% |
| Mar 27 | Guggenheim | Maintains | Buy → Buy | — | $41.58 | $42.33 | +1.8% | +5.4% | -1.6% | -1.8% | -3.5% | -3.1% |
| Mar 21 | Wedbush | Maintains | Neutral → Neutral | — | $45.33 | $46.47 | +2.5% | -5.4% | -4.4% | +0.4% | +1.0% | +5.4% |
| Jan 26 | Wedbush | Maintains | Neutral → Neutral | — | $25.31 | $27.10 | +7.1% | +19.2% | +11.5% | +2.6% | +5.5% | +4.3% |
| Jan 26 | Raymond James | Upgrade | Outperform → Strong Buy | — | $25.31 | $27.10 | +7.1% | +19.2% | +11.5% | +2.6% | +5.5% | +4.3% |
| Dec 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.98 | $16.12 | +0.9% | -0.3% | +0.3% | -3.7% | +1.5% | -1.6% |
| Nov 30 | JP Morgan | Maintains | Overweight → Overweight | — | $13.35 | $13.78 | +3.2% | +1.5% | +2.1% | +0.2% | -2.7% | +2.6% |
| Nov 10 | Jefferies | Upgrade | Hold → Buy | — | $11.51 | $13.00 | +12.9% | +5.5% | +5.1% | +6.7% | -1.9% | -1.0% |
| Sep 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.22 | $14.95 | +5.1% | +11.3% | -4.9% | -7.8% | -1.2% | -5.5% |
| Aug 11 | Wedbush | Maintains | Neutral → Neutral | — | $19.64 | $19.71 | +0.4% | -6.0% | -3.6% | -0.6% | -2.8% | -0.5% |
| Jun 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.00 | $9.01 | +0.1% | -3.3% | -10.7% | +15.8% | +22.2% | +21.4% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.55 | $7.56 | +0.1% | +0.3% | +5.3% | -3.4% | -1.4% | -2.5% |
| May 12 | Wedbush | Maintains | Neutral → Neutral | — | $7.55 | $7.56 | +0.1% | +0.3% | +5.3% | -3.4% | -1.4% | -2.5% |
| Apr 12 | JP Morgan | Maintains | Overweight → Overweight | — | $6.14 | $6.25 | +1.8% | +1.5% | +3.4% | -2.6% | +1.8% | +0.3% |
| Mar 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.26 | $7.29 | +0.4% | +5.0% | -2.4% | +4.3% | -2.6% | -5.7% |
| Jan 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.30 | $7.15 | -60.9% | -64.7% | -13.3% | -2.1% | -1.3% | +7.9% |
| Jan 4 | Wedbush | Downgrade | Outperform → Neutral | — | $18.30 | $7.15 | -60.9% | -64.7% | -13.3% | -2.1% | -1.3% | +7.9% |
| Jan 4 | Jefferies | Downgrade | Buy → Hold | — | $18.30 | $7.15 | -60.9% | -64.7% | -13.3% | -2.1% | -1.3% | +7.9% |
No insider trades available.
8-K · 2.02
!! High
Vera Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Vera Therapeutics reported Q1 2026 earnings results on May 7, with details available in the accompanying press release exhibit for investor assessment of operational performance.
May 7
8-K · 5.02
!!! Very High
Vera Therapeutics, Inc. -- 8-K 5.02: Executive Change
Vera Therapeutics appointed Christopher Hite as a Class III Director, adding board experience that may influence strategic decisions and governance oversight for shareholders.
Mar 9
8-K
Vera Therapeutics, Inc. -- 8-K Filing
Vera Therapeutics reported positive Phase 3 ORIGIN 3 data for atacicept in IgA nephropathy, earning FDA priority review for its biologics license application, strengthening its path to potential market approval.
Feb 26
Data updated apr 27, 2026 7:31am
· Source: massive.com